This study looks at using radiotherapy and an investigational medication called bevacizumab for people with a type of lung cancer, specifically lung adenocarcinoma, that has spread to a few other places in the body (oligometastasis). The study will help us understand how well this treatment works and its safety.

Key Points:

• The study will last until the disease progresses or side effects become too severe. Participants will receive treatment every 3 weeks.
• To join, you must be at least 18 years old, have good organ and bone marrow function, and have lung adenocarcinoma that has spread to 1-5 other areas but does not have certain genetic markers.
• Those with specific heart, blood, or other health problems, or those who have had major surgery recently, cannot join.

If you or someone you know has a lung cancer condition like this, and meets the requirements, this study might be an option. Always discuss with your doctor to understand if it’s the right choice.